O29: Results from a phase 1/2 open-label trial of GTX-102: An investigational antisense oligonucleotide for treatment of patients with Angelman syndrome
Genetics in Medicine Open · 2026 · 4 · 104316
DOI: 10.1016/j.gimo.2026.104316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026. Verfasst von Kimberly Goodspeed und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Goodspeed, K., Cimms, T., Chen, A., Tan, W., Myers, K., Berry-Kravis, E., Weiss, D., Servais, L., & Sell, E. (2026). O29: Results from a phase 1/2 open-label trial of GTX-102: An investigational antisense oligonucleotide for treatment of patients with Angelman syndrome. Genetics in Medicine Open, 4, 104316. https://doi.org/10.1016/j.gimo.2026.104316
Vancouver
Goodspeed K, Cimms T, Chen A, Tan W, Myers K, Berry-Kravis E, et al. O29: Results from a phase 1/2 open-label trial of GTX-102: An investigational antisense oligonucleotide for treatment of patients with Angelman syndrome. Genetics in Medicine Open. 2026;4:104316. doi:10.1016/j.gimo.2026.104316
BibTeX
@article{Goodspeed2026,
author = {Goodspeed, Kimberly and Cimms, Tricia and Chen, Angel and Tan, Wen-Hann and Myers, Kenneth and Berry-Kravis, Elizabeth and Weiss, Deike and Servais, Laurent and Sell, Erick},
title = {O29: Results from a phase 1/2 open-label trial of GTX-102: An investigational antisense oligonucleotide for treatment of patients with Angelman syndrome},
journal = {Genetics in Medicine Open},
year = {2026},
volume = {4},
pages = {104316},
doi = {10.1016/j.gimo.2026.104316}
}
EUVIMED